Brief Report: First-line Pembrolizumab in Metastatic Non-Small Cell Lung Cancer Habouring MET Exon 14 Skipping Mutation and PD-L1 ≥50% (GFPC 01-20 Study)

Clin Lung Cancer. 2022 Dec;23(8):e545-e549. doi: 10.1016/j.cllc.2022.09.002. Epub 2022 Sep 17.
No abstract available

Keywords: Immunotherapy; MET exon 14 skipping mutation; biomarker; non-small cell lung cancer; oncogenic addiction.

Publication types

  • Case Reports

MeSH terms

  • B7-H1 Antigen / genetics
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • Carcinoma, Non-Small-Cell Lung* / pathology
  • Exons / genetics
  • Humans
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / genetics
  • Lung Neoplasms* / pathology
  • Mutation / genetics

Substances

  • B7-H1 Antigen
  • pembrolizumab